**APPENDIX I**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Table A Patient characteristics by categorized carcinoma percentages | | | | | |
|  | **CP-low (< 50%)**  **(*n* = 68)** | | **CP-high (50% or more)**  **(*n* = 86)** | |  |
|  | *n* | *%* | *n* | *%* | *P-value\** |
| Gender |  |  |  |  | NS |
| *Male* | 49 | 72.1 | 51 | 59.3 |  |
| *Female* | 19 | 27.9 | 35 | 40.7 |  |
|  |  |  |  |  |  |
| Age (years) | M 68.2 SD 8.43  (range 49.0-84.0 ) | | M 66.0 SD 11.1  (range 40.0-91.0) | | NS‡ |
|  |  |  |  |  |  |
| Treatment |  |  |  |  | NS |
| *APR* | 34 | 50.0 | 33 | 38.4 |  |
| *LAR* | 23 | 33.8 | 40 | 46.5 |  |
| *Hartmann* | 11 | 16.2 | 13 | 15.1 |  |
|  |  |  |  |  |  |
| T-stage |  |  |  |  | NS |
| *pT1* | 1 | 1.5 | 5 | 5.8 |  |
| *pT2* | 22 | 32.4 | 28 | 32.6 |  |
| *pT3* | 42 | 61.8 | 50 | 58.1 |  |
| *pT4* | 3 | 4.4 | 3 | 3.5 |  |
|  |  |  |  |  |  |
| N-stage |  |  |  |  | NS |
| *pN0* | 37 | 54.4 | 57 | 66.3 |  |
| *N1* | 21 | 30.9 | 18 | 20.9 |  |
| *N2* | 10 | 14.7 | 11 | 12.8 |  |
|  |  |  |  |  |  |
| Stage |  |  |  |  | NS |
| *I* | 18 | 26.5 | 27 | 31.4 |  |
| *II* | 19 | 27.9 | 30 | 34.9 |  |
| *III* | 31 | 45.6 | 29 | 33.7 |  |
|  |  |  |  |  |  |
| Grading |  |  |  |  | NS |
| *Well* | 0 | 0 | 4 | 4.7 |  |
| *Moderate* | 58 | 85.3 | 71 | 82.6 |  |
| *Poor* | 10 | 14.7 | 11 | 12.8 |  |
|  |  |  |  |  |  |
| Adjuvant treatment | 29 | 42.6 | 22 | 25.6 | **0.038**§ |
| *Radiotherapy* | 26 |  | 17 |  |  |
| *Chemoradiotherapy* | 2 |  | 5 |  |  |
| *Chemotherapy* | 1 |  | 0 |  |  |
| *CP* carcinoma percentage; *n* number of patients; *%* percentage; *NS* not significant; *Age* defined as period from birth until date of primary surgery; *LAR* low anterior resection; *APR* abdominoperineal resection; *Hartmann* modulated low anterior resection without the construction of an anastomosis;  *pT* pathological tumor stage; *pN* pathological nodal stage; S*tage* according to UICC/AJCC TNM-classification, 5th edition  \* Pearson *χ*2 test; ‡ Student’s *t*-test; § *P*-value for adjuvant treatment in general | | | | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Table B Survival rates and Log-rank survival statistics for categorized CPs (CP-low: CP < 50%; CP-high: CP > 50% or higher)** | | | | | | | |
|  | *3 years* |  | *5 years* |  | *10 years* |  |  |
|  | *CP-low* | *CP-high* | *CP-low* | *CP-high* | *CP-low* | *CP-high* | *P-value* |
| *OSS* | 0.65 | 0.73 | 0.50 | 0.61 | 0.29 | 0.44 | NS |
| *DSS* | 0.79 | 0.80 | 0.64 | 0.71 | 0.53 | 0.63 | NS |
| *DFS* | 0.69 | 0.68 | 0.57 | 0.61 | 0.57 | 0.59 | NS |
| *CP* carcinoma percentage; *OSS* overall survival; *NS* not significant; *DSS* disease specific survival; *DFS* disease free survival | | | | | | | |